Tuberculosis and HIV/AIDS: Epidemiological and Clinical Aspects (World Perspective)

Naomi Bock; Lee B. Reichman

doi:10.1055/s-2004-829505

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2004; 25(3): 337-344
DOI: 10.1055/s-2004-829505

Published by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Tuberculosis and HIV/AIDS: Epidemiological and Clinical Aspects (World Perspective)

Naomi Bock¹ , Lee B. Reichman²

¹Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, Georgia
²New Jersey Medical School National Tuberculosis Center, Newark, New Jersey

Abstract

Human immunodeficiency virus (HIV) infection is the most powerful known risk factor for progression from latent infection with Mycobacterium tuberculosis to active tuberculosis (TB) disease. The worldwide HIV epidemic has affected TB in every aspect: immunopathology, epidemiology, diagnosis, treatment, and prevention. Of the 42 million people infected with HIV worldwide, more than a quarter of them are also infected with TB, and most live in countries with limited resources for health care in Africa and Asia. This chapter emphasizes HIV-associated TB in resource-limited settings. TB-infected persons with HIV-associated immunosuppression progress to TB disease at a rate of up to 10% per year. Standard TB diagnostic tools have diminished sensitivity in HIV co-infected cases. Standard TB treatment regimens may be less effective, particularly those that do not use a rifamycin throughout. Treatment is further complicated by toxicity, malabsorption, drug-drug interactions and immune reconstitution paradoxical reactions. TB control in the United States was destabilized in part by the HIV epidemic in the early 1990s; massive political will and resources were required to rebuild the public health infrastructure. Africa, Asia, and potentially the former Soviet Union are facing even greater destabilization of TB control due to the dual burden of disease and limited resources. An international response has been initiated but will require even greater political will and resources.

KEYWORDS

Mycobacterium tuberculosis - human immunodeficiency virus

Full Text

References

REFERENCES

1 Corbett E Z, Watt C J, Walker N et al.. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163 1009-1021
2 Rana F S, Hawken M P, Mwachari C et al.. Autopsy study of HIV-1 positive and HIV-1 negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000; 24 23-29
3 Raviglione M C, Harries A D, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS. 1997; 11(suppl B) S115-S123
4 Godrey-Faussett P, Ayles H. Can we control tuberculosis in high HIV prevalence settings?. Tuberculosis. 2003; 83 68-76
5 World Health Organization .Guidelines for Implementing Collaborative TB and HIV Programme Activities. Geneva; World Health Organization 2003
6 Tracevska T, Jansone I, Baumanis V, Marga O, Lillebaek T. Prevalence of Beijing genotype in Latvian multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis. 2003; 7 1097-1103
7 Reichman L B, Tanne J H. Timebomb: The Global Epidemic of Multi-Drug-Resistant Tuberculosis. New York; McGraw-Hill 2002
8 Cantwell M F, Snider D E, Cauthen G M, Onorato I M. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA. 1994; 272 535-539
9 Bloom B R, Murray C JL. Tuberculosis: commentary on a reemergent killer. Science. 1992; 257 1055-1064
10 CDC .HIV/AIDS Surveillance Report. 2002 14: 17
11 Bennett D E, Courval J M, Onorato I M et al.. Prevalence of TB infection in the US population. Abstract #67921. American Public Health Association, 131st Annual Meeting, November 15-19 2003 American Public Health Association Washington, DC;
12 CDC .Reported Tuberculosis in the United States, 2001. Atlanta; U.S. Department of Health and Human Services 2002
13 Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City: turning the tide. N Engl J Med. 1995; 333 229-233
14 Schluger N W, Rom W N. The host immune response to tuberculosis. Am J Respir Crit Care Med. 1998; 157 679-691
15 Schluger N W, Perez D, Lui Y M. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest. 2002; 122 597-602
16 Daley C L, Small P M, Schecter G F et al.. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992; 326 231-235
17 Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001; 358 1678-1693
18 Fitzpatrick L K, Okwera A, Mugerwa R, Ridzon R, Ehiner J, Onorato I. An investigation of suspected exogenous reinfection in tuberculosis patients in Kampal, Uganda. Int J Tuberc Lung Dis. 2002; 6 550-552
19 Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002; 359 2059-2064
20 Ledergerber B, Egger M, Erard V et al.. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV cohort study. JAMA. 1999; 282 2220-2226
21 Goletti D, Weissman D, Jackson R W et al.. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol. 1996; 157 1271-1278
22 Whalen C, Horsburgh R, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Crit Care Med. 1995; 151 129-135
23 Leroy V, Sami R L, Dupon M et al.. Progression of human immunodeficiency virus infection in patients with tuberculosis disease: a cohort study in Bordeaux, France 1988-1994. Am J Epidemiol. 1997; 145 293-300
24 Petruckevitch A, Del Amo J, Phillips A N et al.. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS. 1998; 12 1007-1013
25 Mocroft A J, Lundgren J D, Monforte A D et al.. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol. 1997; 26 400-407
26 Bucher H C, Griffith L E, Guyatt G H et al.. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999; 13 501-507
27 Del Amo J, Malin A S, Pozniak A, De Cock K M. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. AIDS. 1999; 13 1151-1158
28 Jones B E, Young S MM, Antoniskis D et al.. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993; 148 1292-1297
29 Ackah A N, Coulibaly D, Digbeu H et al.. Response to treatment, mortality and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet. 1995; 345 607-610
30 Elliott A M, Halwiindi B, Hayes R J et al.. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg. 1993; 96 1-11
31 Theuer C P, Hopewell P C, Elias D et al.. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis. 1990; 162 8-12
32 Harries A D. Tuberculosis in Africa: clinical presentation and management. Pharmacol Ther. 1996; 73 1-50
33 De Cock K M, Soro B, Coulibaly I M, Lucas S B. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992; 268 1581-1587
34 Toman K. Tuberculosis Case-Finding and World Health Organization, Chemotherapy: Questions and Answers. Geneva; World Health Organization 1979
35 Jones B E, Ryu R, Yang Z et al.. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med. 1997; 157 1270-1273
36 Greenberg S D, Frager D, Suster B et al.. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology. 1994; 193 115-119
37 Pitchenik A E, Rubinson H A. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis. 1985; 131 393-396
38 Perlman D C, el-Sadr W M, Nelson E T et al.. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis. 1997; 25 242-246
39 Graf P. Tuberculosis control in high-prevalence countries. In: Davies PDO Clinical Tuberculosis 1994. London; Chapman & Hall 1994: 325-339
40 Foulds J, O'Brien R. New tools for the diagnosis of tuberculosis: the perspective of developing countries. Int J Tuberc Lung Dis. 1998; 2 778-783
41 Havlir D V, Barnes P F. Current concepts: tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999; 340 367-373
42 Chaisson R E, Clermont H C, Holt E A et al.. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996; 154 1034-1038
43 Perriens J H, St. Louis M E, Mukadi Y B et al.. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995; 332 779-784
44 ATS/CDC/IDSA . Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep. 2003; 52(RR11) 1-77
45 CDC . Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep. 2002; 51 214-215
46 El-Sadr W M, Perlman D C, Matts J P et al.. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998; 26 1148-1158
47 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999; 353 1843-1847
48 Narita M, Ashkin D, Hollender E S, Pitchenik A E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998; 158 157-161
49 Wendel K A, Alwood K S, Gachuhi R, Chaisson R E, Bishai W R, Sterling T R. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest. 2001; 120 193-197
50 CDC . Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-20)
51 Dean G L, Edwards S G, Ives N J et al.. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002; 16 75-83
52 Burman W, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis. 1999; 28 419-430
53 CDC . Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep. 2000; 49 185-189
54 Burman W J, Jones B E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med. 2001; 164 7-12
55 Moreno S, Podzamczer D, Blazquez R et al.. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS. 2001; 15 1185-1187
56 Lopez-Cortes L, Ruiz-Valderas R, Viciana P et al.. Pharmacokinetic interactions between efavirenz andrifampin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002; 41 681-690
57 Veldkamp A, Hoetelmans R, Beijnen J H, Mulder J W, Meenhorst P L. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis. 1999; 29 1586
58 Ribera E, Pou L, Lopez R M et al.. Pharmacokinetic interaction between nevaripine and rifampicin in HIV-infected patients with tuberculsis. J Acquir Immune Defic Syndr. 2001; 28 450-453
59 Nunn P, Kibuga D, Gathua S et al.. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991; 337 627-630
60 Jindani A. IUATLD Clinical Trials Programme Study A (8 months versus 6 months treatment): Initial Results. Paper presented at American Thoracic Society 99th International Conference May 2003 American Thoracic Society New York;
61 Hargreaves N J, Kadzakumanja O, Whitty C JM, Salaniponi F ML, Harries A D, Squire S B. Smear-negative pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis. 2001; 5 847-854
62 Connolly C, Davies G R, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis. 1998; 2 919-925
63 Joint United Nations Programme on HIV/AIDS .Provisional recommendations on the use of cotrimoxazole as part of a minimum package of care in adults and children living with HIV/AIDS in Africa. Available at: http://www.unaids.org/whatsnew/press/eng/pressarc00/recosummary.doc. Accessed October 22, 2003
64 Markowitz N, Hansen N I, Wilcosky T C et al.. Tuberculin and anergy testing in HIV-seropositive persons. Ann Intern Med. 1993; 119 185-193
65 Huebner R E, Schein M F, Hall C A, Barnes S A. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis . Clin Infect Dis. 1994; 19 26-32
66 Center for Disease Control . Anergy skin testing and preventive therapy for HIV-infected persons. MMWR Morb Mortal Wkly Rep. 1997; 46
67 WHO Global Tuberculosis Programme and Global Programme on Vaccines . Statement on BCG revaccination for the prevention of tuberculosis. Wkly Epidemiol Rec. 1995; 70 229-231
68 Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics. 1965; 36 624-627
69 Menzies R I, Vissandjee B. Effect of bacilli Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis. 1992; 145 621-625
70 WHO . Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec. 1999; 46 385-397
71 Markowitz N, Hansen N I, Hopewell P C et al.. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997; 126 123-132
72 Desormeaux J, Johnson M P, Coberly J S et al.. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population. Bull Pan Am Health Org. 1996; 30 1-8
73 Available at: http://www.who.int/gtb/TBHIV/Durban_feb03/index.htm. Accessed October 22, 2003
74 Godfrey-Faussett P, Maher D, Mukadi Y O, Nunn P, Perriens J, Raviglione M. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ. 2002; 80 939-945
75 World Health Organization .Interim Policy on Collaborative TB/HIV Activities. Geneva; World Health Organization 2003
76 Available at: http://www.who.int/mediacentre/factsheets/2003/fs274/en. Accessed October 22, 2003

Naomi BockM.D. M.S.

Global AIDS Program, Centers for Disease Control and Prevention

1600 Clifton Rd., Mail Stop E-04

Atlanta, GA 30333

Email: nbock@cdc.gov